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Abstract
Background: Malaria in pregnancy is a public health problem for endemic countries. Economic evaluations of malaria
preventive strategies in pregnancy are needed to guide health policies.
Methods and Findings: This analysis was carried out in the context of a trial of malaria intermittent preventive treatment in
pregnancy with sulphadoxine-pyrimethamine (IPTp-SP), where both intervention groups received an insecticide treated net
through the antenatal clinic (ANC) in Mozambique. The cost-effectiveness of IPTp-SP on maternal clinical malaria and
neonatal survival was estimated. Correlation and threshold analyses were undertaken to assess the main factors affecting
the economic outcomes and the cut-off values beyond which the intervention is no longer cost-effective. In 2007 US$, the
incremental cost-effectiveness ratio (ICER) for maternal malaria was 41.46 US$ (95% CI 20.5, 96.7) per disability-adjusted life-
year (DALY) averted. The ICER per DALY averted due to the reduction in neonatal mortality was 1.08 US$ (95% CI 0.43, 3.48).
The ICER including both the effect on the mother and on the newborn was 1.02 US$ (95% CI 0.42, 3.21) per DALY averted.
Efficacy was the main factor affecting the economic evaluation of IPTp-SP. The intervention remained cost-effective with an
increase in drug cost per dose up to 11 times in the case of maternal malaria and 183 times in the case of neonatal mortality.
Conclusions: IPTp-SP was highly cost-effective for both prevention of maternal malaria and reduction of neonatal mortality
in Mozambique. These findings are likely to hold for other settings where IPTp-SP is implemented through ANC visits. The
intervention remained cost-effective even with a significant increase in drug and other intervention costs. Improvements in
the protective efficacy of the intervention would increase its cost-effectiveness. Provision of IPTp with a more effective,
although more expensive drug than SP may still remain a cost-effective public health measure to prevent malaria in
pregnancy.
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Introduction
Malaria during pregnancy can result in negative outcomes in
maternal and child health [1,2]. For this reason the World Health
Organization (WHO) currently recommends the administration of
intermittent preventive treatment (IPTp) with sulfadoxine-pyri-
methamine (SP) and the provision of insecticide treated nets
(ITNs) [3]. Interestingly, although IPTp-SP has been recommend-
ed for the last 12 years [4] there is still little and incomplete
information on the economic evaluation of this strategy. All
previously published economic evaluations of IPTp-SP have used
surrogate indicators of infant mortality, such as low birth weight
and parasitemia or placental malaria as surrogate indicators of
maternal morbidity and mortality to calculate disability adjusted
life years (DALYs) [5–9]. Only two cost-effectiveness analysis of
IPTp-SP have been carried out alongside intervention studies
[5,6]. Amid the increasing attention given to malaria eradication
[10,11], there is still a need to conduct economic evaluations of
control strategies in general and specifically in pregnancy, to
inform health policy decision making [12].
IPTp involves giving at least two treatment courses of SP to
pregnant women from the second trimester onwards at least one
month apart. The increasing resistance of the parasite to SP leads
to the need of evaluating safety and efficacy of new drugs for IPTp
[13–15]. Increasing the effectiveness of malaria preventive
interventions in pregnancy would require available safe and more
PLoS ONE | www.plosone.org 1 October 2010 | Volume 5 | Issue 10 | e13407
efficacious drugs for IPTp as well as improving antenatal clinic
(ANC) attendance and the quality of ANC services [16,17].
However, new strategies for effectiveness improvement are likely
to entail extra costs to the health system. As a consequence, the
economic evaluation of IPTp-SP should also include the
estimation of the cut-off levels of the intervention costs beyond
which the strategy ceases to be cost-effective under different
epidemiological conditions, levels of efficacy and factors that may
limit effectiveness.
In order to facilitate the decision making process of malaria
control in pregnancy, we carried out a cost-effectiveness analysis of
IPTp with SP based on efficacy results of a trial in which the
intervention was tested against IPTp with placebo and women in
both trial arms received an ITN. The provision of IPTp and ITNs
was implemented through the ANC of a district hospital in
Southern Mozambique. This is the first cost-effectiveness analysis
of IPTp-SP to consider its incremental effect in addition to ITNs
and to evaluate its consequences on clinical maternal malaria and
on neonatal mortality. The main factors affecting the cost-
effectiveness of the intervention were evaluated, as well as the
cut-off points beyond which IPTp-SP is no longer cost-effective.
Methods
Study area and population
The study was undertaken at the Centro de Investigac¸a˜o em
Sau´de da Manhic¸a (CISM) in Manhic¸a, Maputo Province,
Southern Mozambique. The CISM carries out a Demographic
Surveillance System (DSS) in the Manhic¸a study area, which
includes a population of 80.000 inhabitants. Adjacent to the CISM
is the Manhic¸a District Hospital (MDH), a 110 bed health facility.
The whole Manhic¸a District has an estimated population of
about 130.000 inhabitants. The main local economic activity is
subsistence farming and some workers are employed in two sugar
and fruit processing factories. An increasing number of small and
medium traders have established their activity along the road
Maputo-Beira. The two main towns are Manhic¸a and Xinavane
but most of the population live in small dispersed hamlets. Malaria
transmission in the area is perennial with some seasonality and the
entomological inoculation rate for the year 2002 was 38 infective
bites per person per year [18]. Geographical and demographic
characteristics have been described elsewhere [19,20].
ANC attendance is high in the study area with more than 95%
of the women attending the ANC at least once during pregnancy
(Nhacolo, personal communication).
Bed net use is limited in the area. Around 40% of the
households’ representatives interviewed during a recent study
conducted among the DSS population replied to own at least one
(non-impregnated) bed net. Of those, less than 40% referred that
they had slept under the bed net during the previous rainy season
[21].
Study design
Effects. This economic evaluation was done in the context of
a randomized, placebo-controlled trial of two doses of SP as IPTp.
Pregnant women were enrolled at the ANC and individually
randomised to receive placebo or SP. All participant women
received a long-lasting ITN (LLITN) as part of the study. The
main results of the trial showed that IPTp-SP was efficacious in
reducing clinical malaria during pregnancy [Protective Efficacy
(PE) 40% (95% CI 7.4%, 61.2%); p = 0.020] and neonatal
mortality [PE 61.3% (95% CI 7.4%, 83.8%); p = 0.024] [22,23].
The intervention was safe and well tolerated as shown in other
studies [24–26]. More than 80% of the women reported having
used the ITN during pregnancy and 62% after delivery (Bardajı´ et
al, unpublished). This economic evaluation was included in the
trial protocol. The trial protocol was approved by the National
Mozambican Ethics Review Committee, and the Hospital Clinic
of Barcelona Ethics Review Committee.
Costs
IPTp intervention costs. As variable costs of the
intervention, the value of the nurses’ time to administer the
intervention, as well as drug costs were considered. During real
time observations of routine ANC visits at the MDH, it was
estimated that personnel costs of administering three tablets of SP
to a pregnant woman represented three minutes of a nurse’s full
workload, i.e. 0.70% of her daily wage. International SP drug
prices were used. Drug prices were increased by 10% to include
shipping costs [27]. Fixed costs were represented by the cost of
training health personnel on the administration of IPTp-SP.
Because of the similarities between the two types of preventive
interventions, training costs were assumed to be equal to those
estimated in a previous study on Intermittent Preventive
Treatment of malaria in infants (IPTi) [28]. Other non-recurrent
components considered in the IPTi implementation cost estimate,
such as policy change and sensitisation, strategy management and
development of behaviour change communication materials, were
not included in this study because they were considered negligible
for the implementation of IPTp-SP in Mozambique [29].
Intervention costs for a target of 1000 pregnant women
receiving IPTp-SP at the ANC was equal to the unit fixed costs
component multiplied by 2000 (2 doses*1000 women) plus the unit
variable costs component multiplied by the actual number of doses
delivered. The number of IPTp doses delivered was calculated
considering that of the target of 1000 pregnant women, 98%
attend the ANC at least once and between 85% and 92% at least
twice during pregnancy [30].
Costs of malaria treatment during pregnancy. Health
system costs for the treatment of a malaria episode included
admission costs at the maternity ward in the case of inpatients, or
the cost of attendance and treatment in the case of outpatients
[31]. Unit costs of an admission at the maternity ward (occupied
bed/day) and of an external consultation included all recurrent
components and excluded capital costs. Recurrent costs consisted
of personnel, medical, surgical and laboratory supplies among
other recurrent costs. Unit costs were updated from the year 2000
to the year 2007 using the average annual rate inflation correction
factor and validated during interviews with the administrative staff
of the MDH [32]. Drug costs were added to this estimate. Quinine
was the antimalarial drug administered to admitted pregnant
women and to outpatient pregnant women in the first trimester of
gestation. The combination of SP and artesunate was administered
to outpatient pregnant women who were over the first trimester of
pregnancy. Drug costs for malaria treatment are mostly sustained
by the National Health System in Mozambique, and patients only
pay a small fee when attending government health facilities. Total
admission costs were calculated by multiplying the daily unit cost
of admission at the maternity ward by the average number of
admission days, which were estimated through the household cost
data collection outlined below.
IPTp-SP net intervention costs for 1000 pregnant women
receiving the intervention were calculated as difference between
intervention costs and health system costs for the treatment of
malaria episodes averted.
Household costs of malaria treatment during pregnancy were
collected from July 2007 to May 2008 through standardized
questionnaires administered to pregnant women when leaving the
Cost-Effectiveness of IPTp
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maternity ward of the MDH after being admitted with an episode
of malaria (n= 34), or after attending the outpatient clinic with a
diagnosis of malaria (n= 66). Only those women who signed a
written informed consent had the questionnaire administered.
Direct household costs included transportation to and from the
hospital, food and other expenses. Estimated indirect costs
included reductions in paid and unpaid production (income and
welfare losses) that women incurred due to their illness. Self-
reported time cost was used when women were able to estimate
the amount of money lost because of the break from their routine
activity. The monetary value of self-reported time lost was
estimated according to the minimum wage in force in Mozam-
bique if women could not provide this estimate [33].
Household costs data collected were double entered in FoxPro
(Microsoft Corp., Seattle, WA, USA) and data cleaning and
analysis were performed with STATA 9 (Stata Corporation,
College Station, TX, USA). All cost data are presented in United
States Dollars (US$) for the year 2007.
Sample size for household costs survey. Sample size for
the minimum number of women to be administered with a
questionnaire was calculated using this formula: n = (Z2pq/e2)/{1 +
[(Z2pq/e2)21]/N} [34]. In the formula Z (confidence level) was
assumed to be 95%; e (level of precision) was assumed to be 7%; p
(household costs variability) was assumed to be 30%; q= 12p; N
(population of reference) was represented by 200 pregnant women
with malaria registered at the maternity ward of the MDH during
the year 2006. n resulted to be equal to 91. However, information
on 100 women was collected. Thirty percent of the sample was
assumed to be admission cases [35].
Cost effectiveness analysis
All model inputs were expressed as probability distributions
(Table 1). Bootstrapping techniques were used to calculate
distribution ranges in the case of household costs after assessing
the non-normality of cost distributions through Shapiro-Wilk tests
[36,37]. Ranges were derived from different published sources
when individual data were not available or assumed to be 625%
of the estimated mean value in cases where there was no
information on plausible ranges in the literature [38].
For a reference population of 1000 pregnant women,
incremental cost-effectiveness ratios (ICERs) were calculated by
dividing IPTp-SP intervention costs by the number of Disability-
Adjusted Life Years (DALYs) averted due to the reduction in
maternal clinical malaria, or in neonatal deaths, respectively.
Therefore, ICERs included gross intervention costs and excluded
saving from fewer cases of maternal malaria consequent to the
administration of IPTp-SP. DALYs averted were calculated by
multiplying DALYs lost from maternal malaria or neonatal deaths,
times the effectiveness of the intervention on these two outcomes.
In this calculation, age weighting (b= 0.04) and 3% discount rate
were taken into account, and DALYs were based on standard
measures of disease duration (the duration of a non-complicated
malaria episode effectively treated was assumed to be on average
3.5 days, corresponding to 0.01 years) and impact on the quality of
life (disability weight for an episode of malaria in adults was
assumed to be 0.172) [39]. The effectiveness of the intervention
with respect to the number of maternal malaria episodes and of
neonatal deaths averted was calculated by multiplying the efficacy
of the intervention by the factors that may affect its implemen-
tation, such as ANC attendance. No effect of morbidity due to low
birth weight or other possible effects of malaria in pregnancy have
been included in DALYs calculation.
The analysis was done separated for the mother and for the
newborn in order to highlight the cost-effectiveness of IPTp-SP on
the reduction of neonatal mortality. For the fist time such
reduction was directly associated with the intervention instead of
being mediated by a decrease in low birth weight prevalence or an
increase in average weight at birth [23]. However, an aggregate
ICER was also calculated by dividing intervention costs by the
combined DALYs averted for maternal malaria and neonatal
deaths.
Cost-effectiveness of IPTp-SP on maternal malaria. The
number of malaria episodes averted per 1000 pregnant women
receiving IPTp-SP was calculated by multiplying 1000 by the PE
of the intervention, the malaria incidence [as rate per person-year
at risk (PYAR) in the placebo group] and the percentage of ANC
attendance, at least twice, during pregnancy [30]. DALYs averted
were calculated by multiplying the number of DALYs lost due to
the disease by the reduction of malaria morbidity and mortality as
a result of the intervention. DALYs lost were calculated according
to life expectancy in Mozambique of a 24 years old woman
(average age of women enrolled in the trial), which was of 40.4
years in the year 2006 and according to an estimated average case
fatality rate for malaria in pregnancy of 0.33% [40,41]. This
estimate was based on the assumption that of 25 million
pregnancies in Sub-Saharan Africa being at risk of malaria every
year, 30% would be infected with malaria [42,43]. Since the
number of maternal deaths due to malaria every year is estimated
to be approximately of 25.000, it was calculated that 0.33% of
infected women would die because of the disease [25.000/
(25.000.000*30%)*100 = 0.33%].
Health system savings were calculated by multiplying inpatient
and outpatient health facility costs for malaria treatment by
inpatient and outpatient episodes averted, respectively. Inpatient
malaria episodes averted were the total number of malaria
episodes averted times the proportion of cases that were admitted
to hospital with malaria. Outpatient malaria episodes averted were
the result of the total number of malaria episodes averted times the
percentage of presumptive malaria cases seeking care at
governmental facilities.
Cost-effectiveness of IPTp-SP on neonatal mortali-
ty. DALYs averted were calculated by multiplying the
number of neonatal deaths averted by the number of DALYs
lost due to neonatal mortality. The number of neonatal deaths
averted per 1000 pregnant women receiving IPTp-SP was
calculated by multiplying 1000 by ANC attendance, and by the
reduction of deaths resulting from the intervention [44].
DALYs lost were calculated based on life expectancy at birth
in the DSS area of Manhic¸a, which was of 46.3 years in 2007
(Nhacolo, personal communication).
ICERs are presented as acceptability curves [45,46]. Accept-
ability curves allow the graphic representation of the probability
that IPTp-SP is cost-effective (Y axis) according to the different
investment levels in which policy makers may be able or willing to
pay for each DALY averted (X axis).
Uncertainty of parameters used in the analysis
Probabilistic cost-effectiveness analysis was undertaken through
Monte Carlo simulations using @Risk (version 5.0) add-in tool to
Microsoft Excel (Palisade Corporation, Ithaca, NY, USA).
The main factors affecting the cost-effectiveness of the
intervention were identified in the estimated model by calculating
Spearman’s rank correlation coefficients as a measure of the
magnitude of the association between each variable and the
ICERs. A threshold analysis of the cost-effectiveness of IPTp-SP
was performed to estimate cut-off points beyond which the
prevention is no longer cost-effective. The threshold level of the
Cost-Effectiveness of IPTp
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ICERs used to define the intervention as cost-effective was 129
US$ per DALY averted, while 36 US$ per DALY averted was the
threshold used to define the intervention as highly cost-effective.
These threshold figures were based on previously accepted 1993
and 1996 World Bank definitions and inflated to their 2007
equivalent: 129 and 36 US$ for the year 2007 correspond to 100
and 25 US$ for the year 1993, respectively [47-49]. The cost-
effective intervention threshold was conservatively set at 100
instead of 150 US$ per DALY averted. Probabilistic threshold
analysis was performed on SP price, other intervention costs, case
fatality rate, malaria incidence, protective efficacy and antenatal
clinic attendance. Furthermore, a one-way sensitivity analysis was
undertaken on SP price.
Results
Table 2 shows the results of the cost effectiveness analysis
(CEA). Intervention costs of delivering two doses of IPTp-SP to
1000 pregnant women through the ANC were 435.79 US$ (CI
95% 371.80, 508.00).
Table 1. Input variables of the probabilistic cost-effectiveness analysis of IPTp-SPa.
Probaility input variables
Type of probability
distributionb Low estimate Best estimate High estimate Sources
IPTp intervention costs per dose deliveredc
Drug Triangular 0.06 0.07 0.13 [27]
Personnel Triangular 0.08 0.10 0.13 Observational study
Training Triangular 0.04 0.05 0.07 [28]
Antenatal clinic attendance
At least once Point estimate 0.98 [30]
At least twice Uniform 0.85 0.92 [30]
Epidemiological inputs and efficacy of IPTp-SPa on maternal health
Protective efficacy of IPTp-SPa Triangular 0.074 0.40 0.61 [22]
Malaria incidenced Triangular 0.26 0.35 0.44 [22]
Proportion of malaria cases seeking caree Uniform 0.40 0.60 [53]
Proportion of malaria cases that are hospitalizedf Triangular 0.03 0.04 0.05 [22]
Case Fatality Rate Triangular 0.0026 0.0033 0.0045 Estimate
Household costs for malaria treatment of pregnant womenc
Inpatients
Directg Triangular 212.16 5.10 12.55 Survey
Indirectg Triangular 26.38 5.01 9.02 Survey
Outpatients
Direct Triangular 0.01 0.61 1.21 Survey
Indirect Triangular 1.08 1.49 1.91 Survey
Health system costs for malaria treatment of pregnant womenc
Inpatients
Drugh Triangular 1.28 1.52 2.87 [27]
Inpatient average cost per admission/day Triangular 29.41 39.21 49.01 [31]
Outpatients
Drugi Triangular 1.91 3.97 4.22 [27]
Visits Triangular 0.67 0.90 1.10 [31]
Efficacy of IPTp-SPa on neonatal mortality
Number of neonatal deaths averted due to IPTp-SPa Triangular 0.00 11.00 22.00 [23]
Reduction of neonatal deaths per 1000 mothers
receiving SPl
Triangular 4.96 22.22 39.47 [23]
aIntermittent preventive treatment of malaria in pregnancy with sulphadoxine-pyrimethamine.
bTringular distribution was chosen to be consistent with previous similar studies [53,58].
cin US$ 2007.
dRate per person-year at risk in the placebo group.
eIt indicates the proportion of pregnant women with symptoms of malaria who seek formal health care. The values of the uniform distribution are adapted from Hutton
et al [53]
fIt is assumed that severe cases = hospitalized cases
gThe left limit of the confidence interval is negative due to bootstrapping.
hDrug costs for inpatients refers to intravenous quinine.
iDrug costs for outpatients refers to artesunate plus SP.
lSeven newborns died during the first 28 days of life for each 495 pregnant women receiving SP and 18 newborns died for 493 pregnant women receiving placebo.
Reduction of deaths per 1000 mothers receiving SP is equal to [number of deaths averted/number of mothers in SP group]*1000.
doi:10.1371/journal.pone.0013407.t001
Cost-Effectiveness of IPTp
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Cost-effectiveness of IPTp on maternal health
Per 1000 pregnant women receiving IPTp-SP, the number of
outpatient episodes averted as a result of the intervention was
56.12 (CI 95% 20.50, 95.50) and the number of malaria
admissions averted was 4.49 (CI 95% 1.63, 7.56). The number
of DALYs averted was 12.20 (CI 95% 4.59, 20.81). Intervention
costs per DALYs averted was 41.46 US$ (CI 95% 20.50, 96.70);
its cumulative distribution (acceptability curve) is depicted in
Figure 1.
Per 1000 women receiving IPTp-SP the total health system cost
savings were 422.74 US$ (CI 95% 152.00, 718.00), 43% of which
was due to a reduction in hospital admissions. Net intervention
costs were 13.17 US$ (CI 95% 2292.00, 290.00). With regard to
household costs, for women attending as outpatients, 33.89 US$
(CI 95% 6.10, 77.20) were saved as direct costs and 83.79 US$ (CI
95% 29.60, 148.30) as indirect costs; for admitted women, 8.20
US$ (CI 95% 242.80, 55.80) were saved as direct costs and 11.44
US$ (CI 95% 220.50, 42.70) as indirect costs (Table 2).
Spearman’s rank correlation coefficients showed that the PE of
the intervention was the variable that most affected the ICERs in
the estimated model (Figure 2). The associations between ICER
and SP costs and between ICER and personnel costs were not
strongly significant. The correlation coefficients between health
system’s savings and the PE of IPTp-SP showed a strong
association. A similar association was found between the PE of
IPTp-SP and households’ savings.
According to the probabilistic threshold analysis of the ICER
per DALY averted (Figure 3) IPTp-SP is no longer cost-effective
when the ANC attendance is lower than 37.5%, PE is lower than
15%, malaria incidence is lower than 0.15 person-year at risk, case
fatality rate lower than 0.15%. Furthermore, this analysis suggests
that IPTp-SP is no longer cost-effective when the price of SP per
dose is higher than 0.57 US$ and personnel cost for each dose
delivered is higher than 0.60 US$. When all input variables of the
cost-effectiveness analysis of IPTp-SP are constant (one way
threshold analysis), the price of SP at which the intervention ceases
Table 2. Cost-effectiveness analysis of IPTp-SPa for 1000 pregnant womenb.
Intervention costsc 435.79 (371.80, 508.00)
Treatment savings due to the efficacy of IPTp-SPa on clinical malariac
Health system treatment savings 422.74 (152.00, 718.00)
Outpatient 239.91 (84.00, 432.00)
Inpatient 182.82 (66.30, 308.00)
Households’ outpatient treatment savings 117.69 (40.50, 212.70)
Direct 33.89 (6.10, 77.20)
Indirect 83.79 (29.60, 148.30)
Households’ admission treatment savings 19.64 (239.30, 81.00)
Direct 8.20 (242.80, 55.80)
Indirect 11.44 (220.50, 42.70)
Net intervention costsc on clinical malaria
Intervention costs – health system treatment savings 13.17 (2292.00, 290.00)
Incremental cost effectiveness ratio on clinical malaria
Intervention costs/ Number DALYs avertedd 41.46 (20.50, 96.70)
Effectiveness of IPTp-SPa on clinical malaria
Total number of episodes avertede 112.00 (42.00, 182.00)
Number of outpatient episodes averted 56.12 (20.50, 95.50)
Number of inpatient episodes averted 4.49 (1.63, 7.56)
Number of maternal deaths averted 0.39 (0.143, 0.661)
Number of DALYsd averted 12.20 (4.59, 20.81)
Incremental cost effectiveness ratio on neonatal mortality
Intervention costs/ Number DALYs avertedd 1.08 (0.43, 3.48)
Effectiveness of IPTp-SPa on neonatal mortality
Number of neonatal deaths averted 18.93 (4.39, 33.85)
Number of DALYs avertedd 555.21 (129.00, 992.00)
Combined analysis
Intervention costs/Number of DALYs avertedd 1.02 (0.42, 3.21)
Number of DALYs avertedd 570.95 (236.00, 908.00)
aIntermittent preventive treatment of malaria in pregnancy with sulphadoxine-pyrimethamine.
b95% confidence intervals in brackets.
cin US$ 2007.
dDisability-adjusted life years.
eTotal number of episodes averted is theoretical and relies on the assumption that formal treatment is sought for any case of suspected malaria. The total number is
higher than the sum of inpatients and outpatients episodes averted because number of outpatient episodes considers that only a proportion of pregnant women with
symptoms of malaria, actually, seeks formal treatment.
doi:10.1371/journal.pone.0013407.t002
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to be cost-effective is higher (0.71 US$ per dose) than when the
analysis is done through probabilistic analysis.
Cost-effectiveness of IPTp on neonatal survival
Delivering IPTp-SP to 1000 pregnant women translates into
18.93 (CI 95% 4.39, 33.85) neonatal deaths averted and into
555.21 (CI 95% 129.00, 992.00) DALYs averted (Table 2). The
ICER was 1.08 US$ (CI 95% 0.43, 3.48) per DALY averted. The
cumulative distribution of the ICER is presented in Figure 4.
Spearman’s rank correlation coefficients showed that the PE of
IPTp-SP is the variable having the greatest effect on the economic
outcomes also in the case of neonatal mortality (Figure 2).
Figure 3 shows the threshold values of some variables beyond
which IPTp-SP is no longer highly cost-effective in reducing
neonatal mortality, but remains cost-effective. Such conditions,
according to the probabilistic threshold analysis, are: ANC
attendance lower than 37%; number of neonatal deaths prevented
lower than 4.66; and SP costs as well as personnel costs higher
than 7.90 US$ per dose delivered. One-way threshold analysis
showed that IPTp-SP was still highly cost-effective at a SP price
per dose of 11 US$.
Discussion
The results of the cost-effectiveness evaluation of malaria
prevention in pregnancy with IPTp-SP in this rural area of
Mozambique showed that this intervention is highly cost-effective
when compliance with ITNs use is high. The intervention was
cost-effective even at the 95% confidence higher limits of the
estimated ICERs. IPTp-SP is a very cheap prevention when
provided through the ANC. Net intervention costs for 1000
pregnant women were 13.17 US$ (CI 95% -292.00, 290.00). Net
intervention costs resulted negative in most of the left part of their
distribution and, thus, IPTp-SP is likely to be a cost saving
intervention. In a context of very limited economic resources for
health care this is a very attractive intervention.
Parasite resistance to SP in the study area has been assessed in vivo
in the case of treatment of symptomatic non complicated malaria in
children [50]. However, there is no evidence of parasite resistance to
SP when the drug is used for prevention in asymptomatic individuals,
as in the case of pregnant women attending the ANC [51]. The
reference trial for this economic evaluation assessed the efficacy of
IPT-SP on malaria prevention during pregnancy, and the results
showed that SP was highly efficacious in preventing clinical malaria
30 days after each administration [22]. However, drug resistance can
evolve rapidly and a reduction in the efficacy of SP would worsen the
cost-effectiveness of the intervention. In fact, the lower limit of
protective efficacy allowing to define IPTp-SP as a cost-effective
intervention against maternal malaria was shown to be of 15% in this
study. Fifteen per cent is included in the confidence interval of IPTp-
SP efficacy resulted from the trial [Protective Efficacy (PE) 40% (95%
CI 7.4%, 61.2%); p = 0.020]. However, safety and efficacy of new
drugs for IPTp have been already proved [52]. Any improvement in
antimalarials efficacy would ameliorate the cost-effectiveness of the
intervention despite an increase in its cost, within the boundaries
estimated in this study. Further trials assessing the safety and efficacy
of new antimalarials for IPTp are ongoing [15].
In the context of the trial the compliance of pregnant women
with the use of ITNs was high and, thus, the cost-effectiveness of
IPTp-SP assessed in this study assumes high ITNs coverage [22].
Currently, ITNs are provided for free as part of routine ANC
services in Mozambique. However, their use outside a trial context
should be encouraged to improve compliance at least during
pregnancy and first years of life of the child.
Figure 1. Maternal malaria: acceptability curve of the cost-effectiveness ratio of IPTp-SPa vs hypothetical willingness to payb.
a Intermittent preventive treatment of malaria in pregnancy with sulphadoxine-pyrimethamine. b Acceptability curves were constructed by plotting
the cumulative distribution of ICER of IPTp-SP per DALYs averted. The Y axis can be interpreted as probability that the intervention is cost-effective
for every level of policy makers’ ability or willingness to pay for each DALY averted (X axis). * 36 US$ per DALY averted= threshold of highly cost-
effective intervention; 129 US$ per DALY averted= threshold of cost-effective intervention.
doi:10.1371/journal.pone.0013407.g001
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Malaria infection significantly contributes to maternal morbid-
ity in sub-Saharan Africa. A recent study in Manhic¸a showed that
about a third of pregnant women attending the maternity clinic
of the MDH presented a malaria clinical episode [43]. Maternal
malaria also negatively affects neonatal survival [23]. Thus,
interventions aimed to prevent these negative outcomes are of
major public health relevance. However, a critical consideration
when deciding whether an intervention should be implemented is
its economic implications. Although it has received more
attention recently, little information still exists on the cost-
effectiveness of malaria preventive interventions in pregnancy. All
published reports on the economic evaluation of preventive
Figure 2. Correlation of cost-effectiveness ratios, savings, and input variables (Spearman’s Rank). a Intermittent preventive treatment of
malaria in pregnancy with sulphadoxine-pyrimethamine. bAntenatal Clinic (ANC) attendance at least twice during pregnancy. c Rate per person-year
at risk in the placebo group. d Drug costs for inpatients refers to intravenous quinine. e Drug costs for outpatients are relative to artesunate plus SP.
f It indicates the proportion of pregnant women with symptoms of malaria who seek formal health care.
doi:10.1371/journal.pone.0013407.g002
Figure 3. Threshold analysis of the cost-effectiveness of IPTp-SPa. a Intermittent preventive treatment of malaria in pregnancy with
sulphadoxine-pyrimethamine b 129 US$/DALY averted. c 36 US$/DALY averted. Within the simulation ranges of each variable: * a threshold of 92.92
US$ was reached only. { a threshold of 96.79 US$ was reached only. { a threshold of 85.99 US$ was reached only. j a threshold of 97.25 US$ was
reached only.
doi:10.1371/journal.pone.0013407.g003
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strategies for malaria in pregnancy used surrogate indicators of
mortality to calculate DALYs [6,7,9] and only two cost-
effectiveness analysis were carried out as part of intervention
studies [5,6]. One study was focused on the incremental cost-
effectiveness analysis of administering IPTp-SP through commu-
nity-based delivery compared to the delivery by means of the
ANC and results are not comparable with the current study [5].
The other study, focused on the cost-effectiveness of alternative
antimalarial regimens (chloroquine versus sulfadoxine-pyrimeth-
amine), concluded that SP given during the second and beginning
of the third trimester of pregnancy, was the most cost-effective
option (75 US$ per infant death averted). In this study no savings
due to the intervention were estimated, and infant deaths averted
were extrapolated from the reduction of the low birth weight
prevalence rather than being a direct consequence of the
intervention.
A recent cost-effectiveness analysis of intermittent preventive
treatment of malaria in infants (IPTi) with SP carried out in this
same area of Manhic¸a, also found that the intervention was highly
cost-effective in preventing malaria in infants [53]. It is important
to point out that the delivery of both interventions through already
existing health structures, such as the routine Expanded Program
on Immunization (EPI) and the ANC is probably one of the most
important factors for these strategies to be cost-effective.
In the current study, for DALYs calculation on maternal health
it was assumed that reducing malaria morbidity would translate
into fewer maternal deaths. To calculate the maternal mortality
component of DALYs averted due to IPTp-SP administration, an
average case fatality rate of 0.33% was applied. While there is
insufficient information on how many infected pregnant women
die of malaria in sub-Saharan Africa, the rate applied in this study
appears to be realistic according to the available evidence. It was
assumed that a third of pregnant women living in the study area
were infected with malaria based on a recent report showing that
27% of pregnant women attending a health facility with clinical
complaints suggestive of malaria were parasitemic [43]. The
estimates used in this economic evaluation considered malaria as
an important cause of maternal death in Mozambique as shown in
a recent study on the causes of maternal mortality where malaria
infection accounted for 10% of all maternal deaths in a tertiary
hospital of Maputo [54].
With respect to DALYs calculation on neonatal health, this
economic evaluation differs from previous ones in that mortality
data, derived directly from the main trial, were used to calculate
the mortality component of DALYs averted due to IPTp-SP
administration, which gives more weight to the findings.
Mean values of the ICERs resulting from this study (41.46 and
1.08 US$) indicated cost-effective levels of investment for each
Figure 4. Neonatal mortality: acceptability curve of the cost-effectiveness ratio of IPTp-SPa vs hypothetical willingness to payb.
a Intermittent preventive treatment of malaria in pregnancy with sulphadoxine-pyrimethamine. b Acceptability curves were constructed by plotting
the cumulative distribution of ICER of IPTp-SP per DALYs averted. The Y axis can be interpreted as probability that the intervention is cost-effective
for every level of policy makers’ ability or willingness to pay for each DALY averted (X axis).
doi:10.1371/journal.pone.0013407.g004
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DALY averted. In addition, acceptability curves (figures 1 and 4)
helped defining which would be a cost-effective investment level
per DALY averted according to the health system’s willingness to
pay. Figure 1 shows that if policy makers are willing to pay only 20
US$ or less per DALY averted, the probability that the
intervention is cost-effective is close to 0. At a higher willingness
to pay of 100 US$ per DALY averted the probability that IPTp-SP
is cost effective is close to 100%. A willingness to pay of 6 US$ per
DALY averted, in the case of neonatal mortality, would be high
enough to guarantee at a probability of almost 100% that the
intervention is cost-effective (Figure 4).
A recent economic evaluation estimated the cost-effectiveness of
adding ITNs distribution through ANCs when antenatal services
administer IPTp-SP [38]. Although results of this study and of the
current one are not directly comparable, it may be useful to
comment on the respective acceptability curves. In that study it
was reported that with an investment of 15 US$ (2005 prices) per
DALY averted, the probability of ITNs distribution to be cost-
effective was of almost 50%, and with an investment of 106 US$
the probability would increase to 100%. In contrast, in the current
study, 15 US$ per DALY averted would guarantee a 100%
probability to be highly cost-effective in the case of neonatal
survival, while 106 US$ per DALY would lead to a probability of
about 100% that the intervention is cost-effective on maternal
malaria.
Even if the Mozambican Government highly subsidies the cost
of health care, being unhealthy has a significant negative economic
impact for the households, especially due to the indirect costs of
the illness. In this country, where the Gross Domestic Product
(GDP) per capita in 2007 was 364 US$ (less than 1 US$ per person
per day), the overall (including both direct and indirect
component) cost for the household of an outpatient attendance
or a hospital admission due to malaria, approximately equals the
remuneration of 2 and 10 working days of a person working as
peasant, respectively [55].
Health system and household savings from fewer neonatal
deaths were not included in this economic evaluation. Health
system savings estimation would imply a complex evaluation of the
economic value of the failure of preventing a neonatal death. From
the household point of view, avoiding a child death may have
several social and familial repercussions apart from the direct
monetary savings related to health care that are very difficult to
estimate. An exhaustive economic evaluation would require a long
term analysis focusing on behavioural changes that the death of a
child could cause in the family as a whole, such as future fertility
decisions and consequences on the social and familial role of the
mother of the dead child, among others. It would be also necessary
to include the impact of the decrease in neonatal mortality on
economic growth. On one hand, a decrease in child mortality
lowers the demand for children (demographic transition) and
raises the income per capita. On the other hand, a decrease in
child mortality provides an incentive to invest in education
because of the higher return on investment consequent to the
longer life expectancy the decrease in mortality leads to. Both the
increase in per capita income and in education are essential
premises towards economic growth [56,57]. Nevertheless, it can be
speculated that if such long term consequences were included, the
intervention would be even more advantageous.
Conclusions
IPTp-SP in the context of ITNs is highly cost-effective in
Mozambique mainly because it is administered through already
existing health structures, such as the ANC, and because SP is a
cheap drug. IPTp-SP remains cost-effective even with a wide
increase in both the cost of the drug and in other related
intervention costs. These findings are likely to hold for other
settings where IPTp-SP is implemented through routine ANC
visits. The estimated ICERs leave wide space for all the input
variables to change and for the intervention to remain cost-
effective. The cost-effectiveness of IPTp would highly improve
with an increase in the efficacy of the intervention. In areas such as
Mozambique where malaria in pregnancy represents a major
public health problem, investing in the improvement of the
effectiveness of IPTp is highly recommended.
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